$RGBP Currently there is no effective treatment f

$RGBP Currently there is no effective treatment for severe aplastic anemia. Regen BioPharma believes its HemaXellerate treatment offers hope to those suffering from this disease. The fact that it impacts such a small segment of the population allows Regen to file for orphan drug status. If approved, Regen would be able to receive annual grant funding to defray costs associated with clinical testing, tax credits for clinical research, assistance with clinical research design and a seven year exclusive marketing period after orphan drug status is approved. These benefits of orphan drug status make addressing this deadly disease viable for companies like Regen interested in these specific market niches.

http://tinyurl.com/grmd9vl

$RGBPP #biotech #houseofrespect #jobs #pharma #stocktip #job #science #ipo #Goog #AMGN #BIIB #CELG #GILD #REGN #VRTX #MYL

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!